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The first application of preimplantation genetic diagnosis 
(PGD) recently celebrated its 25th birthday. Aside from the 
very early days when chromosomal diagnoses were used (by 
sexing) for the selective implantation of embryos unaffected 
by sex linked disorders, the paths of chromosomal and 
monogenic PGD have diverged. For monogenic disorders, 
progress has been impeded by the need to tailor each 
diagnosis to the mutation in question. For chromosomal 
diagnoses, fluorescent in situ hybridization (FISH) 
technology was replaced by array comparative genomic 
hybridization (aCGH), and then next generation sequencing 
(NGS). Karyomapping is a novel approach that allows the 
detection of the inheritance of (grand) parental haploblocks 
through the identification of inherited chromosomal 
segments. It involves genome-wide single nucleotide 
polymorphism (SNP) analysis of parental DNA, a reference 
from a related individual of known disease status (typically 
an affected child) and amplified DNA form biopsied cells of 
the (usually blastocyst) embryos in question. Identification of 
informative loci for each of four parental haplotypes is 
followed by direct comparison to the reference, ultimately 
creating a Karyomap. The Karyomapping programme 
(Illumina) displays homologous chromosomes, points of 
crossing over and the haplotype of each of the embryos. It 
also detects meiotic trisomy, monosomy, triploidy and 
uniparental heterodisomy (some of which NGS and aCGH 
will not). ,QKHUHQWLQWKHGHVLJQLVWKHDQDO\VLVRI³NH\613V´
(heterozygous informative calls) thereby avoiding the risk of 
misdiagnoses caused by the phenomenon of allele drop out 
(ADO). Karyomapping is currently in use for the detection of 
monogenic disorders and around 1000 clinics offer it 
worldwide making use of about 20 diagnostic laboratories. At 
the time of writing, over two and a half thousand clinical 
cases have been performed. Because of the limited detection 
of some post-zygotic errors such as post-zygotic trisomy 
which can also lead to mosaicism, Karyomapping has not yet 
been fully applied clinically for aneuploidy screening. The 
diagnostic potential of the technique will be fully recognised 
with the application of this technology on clinical cases.  
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1. A brief history of PGD 
Preimplantation genetic diagnosis 
(PGD) involves the genetic testing of 
oocytes or IVF embryos facilitating selective 
transfer of apparently genetically normal 
embryos (Handyside, 2011). PGD 
collectively refers to the diagnosis of 
monogenic disorders, human leukocyte 
antigen (HLA) typing, detection of 
unbalanced chromosome rearrangements 
ahead of implantation to reduce the risk of 
babies born with congenital abnormalities or 
implantation failure and/or pregnancy loss 
(Braude et al., 2002; Frumkin et al., 2008; 
Harton et al., 2011b). The first reported case 
of PGD in non-human species was sex 
selection of rabbits performed by Bob 
Edwards and Richard Gardner (Gardner and 
Edwards, 1968). In 1990, the first clinical 
cases in humans were performed for two 
couples at risk of transmitting X-linked-
Adrenoleukodystrophy (X-ALD) and X-
linked mental retardation (Handyside et al., 
1990) with the use of sex-chromosome 
specific primers. Later the first PGD for an 
autosomal recessive monogenic disorder 
(Cystic Fibrosis, ǻF508 mutation of the 
CFTR gene) was announced (in 1992) 
(Handyside et al., 1992). As previously 
alluded to, PGD has come to refer not only 
the detection of specific monogenic traits but 
also the elimination of chromosomally 
unbalanced products from rearrangement 
carriers and the selection of human 
leukocyte antigen (HLA) identical embryos 
ZKLFK PLJKW VHUYH DV SRWHQWLDO µVDYLRXU
VLEOLQJV¶ IRU DIIHFWHG LQGLYLGXDOV LQ QHHG RI
bone-marrow transfer (Kahraman et al., 
2014). In contrast, preimplantation genetic 
screening (PGS), sometimes referred to as 
PGD-A, specifically pertains to aneuploidy 
assessment in embryos e.g. for referral 
categories such as advanced maternal age, 
recurrent implantation failure or recurrent 
miscarriage (Delhanty et al., 1993; Geraedts 
and De Wert, 2009; Geraedts, 2010; Harper 
and SenGupta, 2012b; Traeger-Synodinos 
and Staessen, 2014). PGD can be applied to 
detect any single gene mutation, but the 
³KHDGOLQH´GLVHDVHVWHQGWREH cystic fibrosis, 
beta-thalassemia, myotonic dystrophy, 
+XQWLQJWRQ¶V GLVHDVH DQG IUDJLOH ; (Harper 
and SenGupta, 2012b; Spits and Sermon, 
2009). However, WKHµholy grail¶ of PGD is a 
single universal test that will detect any 
monogenic and all chromosomal disorders 
simultaneously (Handyside, 2015; Thornhill 
et al., 2015). 
Historically, it was the development of 
polymerase chain reaction (PCR) to be 
sensitive enough to work on single cells that 
heralded techniques for mutation detection 
in this setting (BenǦNagi et al., 2016; 
Handyside et al., 2004; Thornhill and Snow, 
2002). The inherent problems associated 
with such diagnostic tests however lie in 
their sensitivity and in the issue of 
contamination. In terms of sensitivity, the 
tiny amount of DNA (5±10pg) present in a 
single cell that needs to be analysed raises 
problems of amplification failure and allele 
drop out (ADO) (i.e. allele specific 
amplification that could lead to a 
heterozygote being diagnosed as a 
homozygote). Regarding contamination, all 
precautions must be taken to ensure that no 
amount of contaminating DNA enters the 
reaction tube (Thornhill and Snow, 2002). 
This has been a problem from even the 
earliest days of PGD (Handyside et al., 
1990) even when amplifying repetitive Y-
specific sequences (e.g. (Chong et al., 1993; 
Hashiba et al., 1999; Levinson et al., 1995; 
Nakahori et al., 1991). Nested PCR (a 
second round of singleplex PCR using the 
first multiplex as a template) increased 
specificity and thus the ability to detect 
diseases such as cystic fibrosis and Alpha-1 
Antitrypsin (A1AT) deficiency (Handyside 
et al., 1992). Countless other mutations 
followed (e.g. (Dahdouh et al., 2015; Hussey 
et al., 1999; Liu et al., 1995; Ray et al., 
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Human genome sequencing data 
(International Human Genome Sequencing 
Consortium, 2004; Lander et al., 2001; 
Sachidanandam et al., 2001; Venter et al., 
2001) revealed polymorphic markers that 
can be used in a multiplex PCR strategy 
(Thornhill et al., 2015). In particular, 
analysis of short tandem repeat (STR) 
markers (principally tetranucleotide repeats) 
facilitated analysis not only of the mutation 
in question but of linked markers around the 
gene. Such strategies minimised the 
problems caused by ADO and contamination 
as each individual analysis confirms the 
other (Harton et al., 2011a; Thornhill et al., 
2015). The technology was taken a step 
further with the adoption of whole genomic 
amplification e.g. multiple displacement 
amplification (MDA) (Handyside et al., 
2004; Hellani et al., 2008), facilitating 
multiplex PCRs and chromosome copy 
number detection (Dahdouh et al., 2015) ± 
see later. PCR with fluorescently labelled 
primers also facilitated more accurate 
detection and multiplexing (Ao et al., 1998; 
De Rycke, 2010; Spits and Sermon, 2009). 
Using this approach over a 10-year period 
(1997-2007) they reported that the 
misdiagnosis rate was 10/3727 (0.27%) 
(BenǦNagi et al., 2016; Harper et al., 2012a). 
This also allowed for analysis of so called 
saviour siblings (Handyside and Xu, 2012; 
Renwick et al., 2010) and ultimately became 
the established approach for PGD 
(Fiorentino et al., 2004; Handyside, 2015). 
The main issue with this approach is that it 
needs to be tailored to the patients in 
question, leading to an inevitable (and often 
stressful) waiting period where primers are 
designed and tested for couples. 
Furthermore, it was limited in its ability to 
detect chromosome abnormalities (Ata et al., 
2012; Konstantinidis et al., 2015; 0XQQp
2006; 0XQQp HW DO ; Thornhill et al., 
2015). 
Following the ultimately unreliable 
PCR sexing strategies attempts to sex 
preimplantation embryos (Handyside et al., 
1990), attention turned to fluorescence in-
situ hybridisation (FISH) using sex 
chromosome specific probes (Griffin et al., 
1991). Clinical application followed (Griffin 
et al., 1994; Griffin et al., 1992; Griffin et 
al., 1993) from 1992-1994, 27 treatment 
cycles ensued, leading to 9 in and 5 female 
live births (Delhanty et al., 1993; Griffin et 
al., 1994; Griffin et al., 1993). FISH was 
then applied to translocation detection and 
aneuploidy screening (0XQQp HW DO ; 
0XQQp DQG &RKHQ ; 1998; 0XQQp et 
al., 1994) and became the most common 
form of PGD. Referral categories were 
advanced maternal age (AMA), recurrent 
miscarriage (RM), recurrent implantation 
failure (RIF) and severe male factor 
infertility. The approach made use of 
fluorescent probes chiefly for chromosomes 
13, 16, 18, 21, 22 (X and Y) (0XQQpHWDO
1996; 0XQQp and Cohen, 1993; 1998; 
0XQQp HW DO ) but was the subject of 
controversy in the field (Summers and 
Foland, 2009), with randomized controlled 
trials indicating no clear benefit for using it. 
It is now a matter of historical record that 
one study (Mastenbroek et al., 2007) 
provided evidence that there was a 
detrimental effect of PGS, with others 
demonstrating no benefit (Blockeel et al., 
2008; Debrock et al., 2010; Hardarson et al., 
2008; Jansen et al., 2008; Mersereau et al., 
2008; Meyer et al., 2009; Schoolcraft et al., 
2009; Staessen et al., 2008), and 5-7 colour 
FISH strategies were largely discontinued. 
Even though 24 chromosome FISH was 
successfully applied to human embryos 
(Ioannou et al., 2012; Ioannou et al., 2011) 
there were technical problems with 
overlapping signals, failed probes, etc. 
condemning FISH to being a research tool 
only (albeit a useful one) for looking at 
phenomena such as nuclear organization and 
mosaicism. FISH still persists in some PGD 
clinics however array comparative genomic 
hybridization (aCGH) and next generation 
sequencing (NGS) have largely replaced it.  
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Comparative genomic hybridisation 
(CGH) took the principles of FISH one step 
further, by using differentially labelled test 
and control (normal) DNA, that are 
competitively hybridized to metaphase 
chromosomes (Theisen, 2008). Unlike FISH, 
CGH allowed for the more rapid assessment 
of chromosome copy number in the entire 
genome (Forozan et al., 1997; Spelcher et 
al., 1993) but was limited to a resolution of 
approximately 5-10Mb in most clinical 
applications (Kirchhoff et al., 1998; Lichter 
et al., 2000). Due to its limitations, this 
technology fell out of favour for clinical 
diagnosis, therefore other techniques were 
developed, including aCGH and NGS as 
mentioned previously.  
Both aCGH and NGS require whole 
genome amplification strategies such as 
multiple displacement amplification (MDA) 
or degenerate oligonucleotide primed-PCR 
(DOP-PCR). Array CGH involves 
fluorescent labeling of a test DNA sample 
and a reference (normal) in two different 
fluorescent colours (De Ravel et al., 2007). 
Simultaneous hybridization to a tiling path 
microarray precedes per-chromosome colour 
ratio analysis ± deviations from 1:1 are 
indicative of aneuploidy, deletions and 
duplications (Fishel et al., 2010; Le Caignec 
et al., 2006; Traversa et al., 2011; Vanneste 
et al., 2009). At a similar time, Treff and 
colleagues developed and validated real-time 
quantitative PCR (RT-qPCR) (Scott et al., 
2013b; Treff and Scott, 2013b; Treff et al., 
2012). In RT-qPCR samples undergo a pre-
amplification step, followed by a high-order 
multiplex PCR reaction to amplify two 
regions on each arm of all the chromosomes. 
Rapid quantification of each product using 
RT-qPCR then allows for the evaluation of 
copy number over the whole genome 
(Dahdouh et al., 2015). Using this technique, 
PCR is performed directly on the sample, 
without a whole genome amplification 
(WGA) step required in technology such as 
aCGH and SNP microarrays (see below). 
However, this means that RT-qPCR can only 
be used on trophectoderm samples, and so 
sufficient blastocyst embryos need to be 
available (Dahdouh et al., 2015; Treff et al., 
2012). 
Around the time of the aCGH 
renaissance, biopsy strategies switched from 
cleavage stage to blastocyst stage, and 
aCGH has recently largely been replaced by 
NGS due to the availability of benchtop 
sequencing technology. To detect 
aneuploidy by this approach fragmentation 
of the whole genome amplified DNA into 
100±200 base pairs pieces is essential. 
Sequencing using fluorescent tags ensues to 
indicate the relevant sample, facilitating low 
cost, high throughput analysis (Fiorentino et 
al., 2014). Sequence data is compared with a 
reference genome and then the process 
LQYROYHV VLPSOH ³ELQQLQJ´ DQG FRXQWLQJ RI
sequences to generate copy number 
information (Fiorentino et al., 2014). In 
other words, the number of sequences 
counted from a specific chromosome is 
proportional to the chromosome copy 
number, leading to detection of monosomy, 
trisomy or segmental alterations (Handyside, 
2013; Handyside and Wells, 2013). NGS has 
a greater dynamic range than aCGH and 
represents the current state of the art for 
aneuploidy detection for PGD. 
2. Single nucleotide polymorphism 
arrays (SNP chips) 
Specialist microarrays detect 
thousands of SNPs across the genome in a 
range of cell types including human embryos 
(Handyside, 2015). Initially developed for 
genome wide association studies (GWAS), 
SNP chips represent biallelic loci where each 
allele is of roughly a similar frequency 
(Habela and Hamosh, 2013; LaFramboise, 
2009). Probing SNP chips leads to each 
allele being differentially fluorescently 
labelled thereby detecting homozygotes and 
heterozygotes and a binary readout at each 
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locus e.g. AA, AB, BB. SNPS are located 
mostly in non-coding regions (around 40 
million are validated in the human genome) 
with SNP chips typically containing 660,000 
to 2 million loci spread roughly evenly along 
the length of all human chromosomes 
(Dahdouh et al., 2015).  
As SNPs are biallelic in nature, they 
are theoretically less informative than STR 
markers (Handyside, 2015). However, given 
the information of parental genotype and a 
relative of known disease status, the four 
distinct sets of markers can be identified 
along the length of each parental 
chromosome for each tested SNPs 
(Handyside, 2015). Such an approach has 
been used for linkage analysis for 
monogenic disease detection (Rabinowitz et 
al., 2011) and detection of chromosome 
abnormalities (Treff et al., 2011) (Dahdouh 
et al., 2015); the Karyomapping technique 
combines these two strategies. 
3. Karyomapping 
Karyomapping (Handyside et al., 
2010) determines the inheritance from the 
parental (or grandparental) chromosomes 
through the recapitulation of haploblocks or 
inherited chromosomal segments). The 
approach involves genome-wide SNP 
analysis of parental DNA, amplified embryo 
DNA and an appropriatHµUHIHUHQFH¶such as 
a close relative (typically an older, affected 
child is used).  
The initial stage is the identification of 
µLQIRUPDWLYH¶ ORFL IRU HDFK RI WKH SDUHQWDO
haplotypes at which where parent is 
homozygous and another heterozygous 
(Natesan et al., 2014a). This is analogous to 
D³EDFNFURVV´WKDWZHOHDrn about in genetics 
101. These informative loci are then 
compared to the reference DNA in order to 
establish phase (assign a reference 
³DIIHFWHG´ KDSORW\SH. After this the 
genotype of each embryo is compared to the 
reference to establish similarity or difference 
at each informative locus. The result is a 
karyomap (figure 1) that displays 
homologous chromosomes as well as points 
of meiotic crossing over.  
Direct comparison of the haploblock at 
the chromosomal locus of interest in the 
reference with those of each of the embryos 
in question (figure 1) allows the diagnosis of 
the presence or absence of a disease causing 
allele (Handyside, 2015). This is achieved 
using the principles of genetic linkage 
established by Morgan and Sturtevant in the 
1930s and does not involve direct mutation 
testing. One of the important advantages of 
Karyomapping is that it can also be applied 
for the diagnosis of meiotic trisomy (figure 1 
right), monosomy, triploidy, parthenogenetic 
activation and uniparental heterodisomy; as 
well as patterns of genomic duplication seen 
in, for example, hydatidiform moles 
(Handyside et al., 2010; Natesan et al., 
2014a; Natesan et al., 2014b). When 
analysing the Karyomapping programme 
output, monosomies and segmental deletions 
are visualised as absence of haploblocks 
from one parent.  Meiotic (but not post-
zygotic) trisomies are visualised as both 
haplotypes on a section of the chromosome, 
reduced to homozygosity after a crossing 
over event. Furthermore, meiosis I and 
meiosis II errors can potentially be 
distinguished depending on whether the 
³GRXEOH KDSORW\SH´ SDWWHUQ LQYROYHV WKH
centromere of the chromosome (Handyside 
et al., 2010). Moreover, Karyomapping only 
involves the detection of heterozygous SNP 
calls. These are termed ³NH\613V´and, by 
gathering the information from thousands of 
key SNPs, the misdiagnosis risks associated 
with ADO are eliminated.  
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Figure 1.  Karyomapping output of the RARS2 gene on chromosome 6q15 (linked to pontocerebellar 
hypoplasia). From left to right, the red and blue bars (far left) are the paternal genotype, the yellow and 
green bars the maternal genotype. The blue and yellow bars are the reference (affected sibling), the 
remainder are embryonic genotypes showing (grand)parental inheritance of haploblocks. In embryo 9 (far 
right) the rapid alternating yellow and green bars represent a meiotic maternal trisomy (probably meiosis 
II as the pattern is not present around the centromere). 
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Karyomapping therefore facilitates the 
simultaneous detection of monogenic and 
chromosomal disorders in a single test 
requiring only minimal patient work up 
(BenǦNagi et al., 2016; Dahdouh et al., 2015; 
Handyside et al., 2010). When applied 
clinically, although Karyomapping can be 
used on any SNP chip with reasonable 
genome coverage (or in principle on NGS 
data) it uses exclusively a dedicated Illumina 
SNP chip with ~300,000 SNPs and a 
bespoke software suite for visualization. 
Karyomapping was validated using a blinded 
retrospective analysis by comparison with an 
STR marker and mutation detection 
approach (see above). The original studies in 
this regard were two case reports where 
Karyomapping was run in parallel with 
conventional analysis for Smith Lemli Opitz 
Syndrome and Marfan Syndrome 
respectively (Natesan et al., 2014b; 
Thornhill et al., 2015). The first of these 
revealed full concordance with the clinical 
analysis of the samples by STR analysis and 
for aneuploidy testing (Natesan et al., 2014a; 
Natesan et al., 2014b). The second 
(Thornhill et al., 2015) established that both 
approaches diagnosed disease status with 
high efficiency and accuracy but that 
Karyomapping was a considerably more 
time-efficient process given that the pre-
PGD patient work-up was much shorter 
(Thornhill et al., 2015). Both led to 
unaffected, chromosomally normal live 
births. A further study used Karyomapping 
for detection of TSC2 (tuberous sclerosis) 
mutations (*LPpQH] HW DO ). In this 
case Karyomapping was able to detect the 
mutation whereas conventional analysis was 
not and led to the birth of an unaffected 
child. (*LPpQH] HW DO ). Analysis of 
subsequent multiple cases compared 
Karyomapping with direct mutation analysis 
in 218 embryos from 44 IVF cycles. The 
authors established that Karyomapping 
produces the same result as mutation 
analysis in 213/218 (97.7%) cases and that 
non-concordance was a result of 
consanguinity (Natesan et al., 2014b). 
7KH SRWHQWLDOO\ XELTXLWRXV ³SODWIRUP
LQGHSHQGHQW´QDWXUHRI.DU\RPDSSLQJLQIHUV
D FHUWDLQ GHJUHH RI ³IXWXUH SURRILQJ,´
particularly as the output is binary i.e. a 
series of AA, AB and BB biallelic genotypes 
(*LPpQH] HW DO ). It is noteworthy 
however, that even when we consider 
continually improving whole genome 
amplification protocols, gaps are bound to 
appear for technical reasons associated with 
the amplification from such a small 
template. Karyomapping has the potential to 
combat this problem by refining the 
algorithms to predict the likely genotype by 
further linkage analysis (*LPpQH] HW DO
2015). In the future, there is a possibility of 
combining Karyomapping with allele 
intensity measurements for the detection of 
non-meiotic trisomies and duplications 
(Rabinowitz et al., 2012; Zamani Esteki et 
al., 2015a) thereby distinguishing meiosis I, 
meiosis II and post-zygotic errors (*LPpQH]
et al., 2015). This is clinically significant 
because mosaic trisomies of meiotic origin 
usually lead to clinical problems; however, 
those of post-zygotic origin can, in certain 
circumstances, lead to unaffected live births.  
Whether we should use PGS at all still 
remains the topic of controversial debate; 
however, there is increasing evidence of its 
efficacy in improving IVF success and 
reducing the risk of miscarriage (Forman et 
al., 2013a; Forman et al., 2013b; *LPpQH]HW
al., 2015; Scott et al., 2013b; Yang et al., 
2012). From a clinical point of view, the 
additional information about the origin of the 
chromosomal error facilitated by 
Karyomapping (but not other PGD 
strategies) has the potential to aid couples to 
establish future treatment regimens; donor 
gametes may be an option (Thornhill et al., 
2015). 
Despite its many advantages, 
Karyomapping is limited in a number of 
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areas. The inherent requirement of DNA 
from a family member with known disease 
status (e.g. affected sibling) particularly in 
dominant disorders that may shorten life 
span thereby (leading to such an individual 
not being available) is one example. Another 
is, if a meiotic cross over in either parent, 
reference individual or embryo juxtaposes 
the locus, this may lead to difficulties in data 
interpretation and thus an inconclusive 
diagnosis. Karyomapping will not detect de 
novo mutations other than those that are 
inherited by Mendelian pattern (Rechitsky et 
al., 2011). A final problem (hitherto already 
mentioned) is the fact that Karyomapping 
cannot easily detect post-zygotic trisomies 
unless combined with quantitative 
approaches such as NGS, aCGH or allele 
intensity measurement. 
Although patient work up for 
Karyomapping is acknowledged to be 
shorter than that of other methods for 
mutation detection, disorders that are not 
already established by PGD technologies 
will need STR marker tests before 
Karyomapping can be used. In these cases, 
the work up time for Karyomapping is the 
same as other technologies. It is important to 
note that there are cost implications 
regarding the implementation of 
Karyomapping. If the lab follows the 
published Illumina protocol, Karyomapping 
UHTXLUHV  SURGXFWV 6XUH0'$ '1$
$QDO\VLV .LW WKH L6FDQ 6\VWHP RU
1H[W6HT  6\VWHP DQG %OXH)XVH
Multi analysis software (Illumina 2015). The 
scanning system required to read the 
BeadChips is different for those required for 
1*6 9HUL6HT DQG Karyomapping 
requires MDA to amplify the DNA instead 
of PCR-based methods commonly used in 
aCGH and NGS. Due to these requirements, 
there is also a need for dedicated workrooms 
for each stage of sample preparation that 
adds to the logistical costs of running a 
Karyomapping assay.   
4. Alternatives to Karyomapping 
As previously mentioned, dectection  
of both monogenic disorders and 
chromosomal abnormalities simultaneously 
is of paramount importance, therefore 
different methods have been developed. One 
suggestion is the combination of classical 
PGD techniques, such as STR+direct 
mutation analysis combined with aneuploidy 
testing through the use of aCGH (Rechitsky 
et al., 2015). This method was shown to 
increase implantation rates and significantly 
reduce miscarriage rates, however it requires 
different experimental setup leading 
potentially to increased time and cost within 
the diagnostic laboratory (Rechitsky et al., 
2015). 
Treff et al. developed the use of RT-
qPCR for the simultaneous detection of 
monogenic disorders and aneuploidy in IVF 
derived human embryos. This technique is 
based around a targeted NGS strategy and a 
multiplex PCR reaction that had targeted the 
required mutation site and chromosome-
specific target sequences (Treff et al., 
2013a). Interestingly, with this technique the 
necessary read depth for accurate sequencing 
of the mutation site is reduced per 
chromosome copy number, which allows for 
a reduction in per sample cost as well as the 
time required to run the test (Dahdouh et al., 
2015). Zimmerman and colleagues 
determined that this strategy was more 
reliable than other techniques (Zimmerman 
et al., 2016) with 303/304 (99.7%) embryos 
getting a definitive diagnosis and 1/304 
(0.3%) recorded as inconclusive due to a 
recombination event. This study also 
demonstrated an 82% (27/33) pregnancy rate 
(Zimmerman et al., 2016). 
Another interesting method is the use 
of NGS technology with linkage analysis 
described by Yan and colleagues. This 
WHFKQLTXH KDV EHHQ ODEHOOHG ³PXWDWHG allele 
revealed by sequencing with aneuploidy and 
OLQNDJHDQDO\VHV´ 0$56$/$ (Yan et al., 
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2015) and involves multiple annealing and 
looping-based amplification cycles 
(MALBAC) for whole-genome 
amplification. Aneuploidy is then detected 
by copy number variations (CNVs), then 
detection of single-nucleotide variations 
(SNVs) in the PCR amplified MALBAC 
product determines the disease status of the 
sample. The false-positive and false-negative 
SNVs are avoided by using an NGS based 
linkage analysis (Yan et al., 2015), and 
importantly this technology has been used to 
achieve two viable and healthy live births 
(Yan et al., 2015). 
Haplarithmisis (Zamani Esteki, 2015b; 
Zamani Esteki et al., 2015a) is an extension 
of Karyomapping technology that allows B 
allele frequencies to be called as well as the 
standard AA, BB or AB alleles we expect 
from SNP data. Zamani et al. argue that the 
process of whole-genome amplification is in 
itself problematic due to the introduction of 
artefacts, thus other haplotyping methods 
suffer from error-prone SNP genotypes (AA, 
AB, BB) (Zamani Esteki, 2015b; Zamani 
Esteki et al., 2015a). Haplarithmisis has been 
shown to diagnose specific disease causing 
alleles throughout the genome, as well as 
indicating the presence of numerical and 
structural chromosomal abnormalities in the 
embryos. Furthermore, it has been shown 
that using this technique, meiotic segregation 
errors can be distinguished from mitotic ones 
(Zamani Esteki, 2015b). 
5. State of the ART 
Karyomapping was first 
commercialized by Illumina in 2013 and is 
currently a routine procedure for PGD 
detection of single gene disorders. At time of 
writing (April 2017) around 1000 clinics 
worldwide offer karyomapping, handled 
largely by 20 diagnostic laboratories 
(personal communication from PGD 
international society meeting, Valencia 
March 2017) with ~2500 cycles currently 
performed. The inability to detect post-
zygotic trisomy reliably however and the 
ever-present problem of mosaicism means 
that Karyomapping is not widely used yet 
for aneuploidy screening. Presentations at 
the Valencia meeting are however describing 
strategies of combining NGS with 
Karyomapping so that copy number 
difference (meiotic and post-zygotic) can be 
detected alongside monogenic defects.  
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